Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 9/20 | 0.45 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | DUT | P33316 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5199324 | 0.84 | DGAT1 (0.37) | DGAT1DUT | |
| SCHEMBL20009936 | 0.81 | DGAT1 (0.30) | DGAT1 | |
| SCHEMBL9638271 | 0.79 | DGAT1 (0.41) | DGAT1DUT | |
| SCHEMBL1488779 | 0.78 | KMT2A (0.43) | DGAT1 | |
| SCHEMBL9638951 | 0.77 | DGAT1 (0.65) | DGAT1 | |
| SCHEMBL3070906 | 0.77 | DGAT1 (0.36) | DGAT1 | |
| Hydrochloric Acid SCHEMBL15455783 | 0.76 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL1126106 | 0.76 | TLR8 (0.47) | DGAT1 | |
| SCHEMBL3574886 | 0.76 | DGAT1 (0.42) | DGAT1DUT | |
| SCHEMBL17810435 | 0.76 | DGAT1 (0.37) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250352549-A1 | SUBSTITUTED HETEROCYCLIC COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | AVELOS THERAPEUTICS INC. (KR) | 2025-11-20 | — | — | US | disclosed |
| EP-4634192-A1 | SUBSTITUTED HETEROCYCLIC COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | Avelos Therapeutics Inc. (KR) | 2025-10-22 | — | — | EP | disclosed |
| WO-2024128741-A9 | SUBSTITUTED HETEROCYCLIC COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | AVELOS THERAPEUTICS INC. (KR) | 2025-05-30 | — | — | WO | disclosed |
| CN-119836421-A | USP1 inhibitors and uses thereof | 森韬医药美国公司 | 2025-04-15 | — | — | CN | disclosed |
| WO-2024128741-A1 | SUBSTITUTED HETEROCYCLIC COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | AVELOS THERAPEUTICS INC. (KR) | 2024-06-20 | — | — | WO | disclosed |
| CN-117529476-A | Preparation of substituted 1, 2-diamino heterocyclic derivatives and their use as medicaments | 亚飞络思制药公司 | 2024-02-06 | — | — | CN | disclosed |
| EP-4058015-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
| US-20180086747-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20180086747-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20180086747-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2018-03-29 | — | — | US | disclosed |
| WO-2018057808-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250352549-A1 | SUBSTITUTED HETEROCYCLIC COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE | MAST1, MAST3, MAST4 | DGAT1 4170/4885ALOX5AP 4145/4885FEN1 4679/4885 |
| US-20180086747-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3CA, AKT3, TNNI3K | DGAT1 3929/4885ALOX5AP 4864/4885FEN1 3562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.